Congressional 45-day review period included in reg reform measure approved by Senate Govt. Affairs Cmte.
Executive Summary
CONGRESSIONAL 45-DAY REVIEW OF AGENCY RULES INCLUDED IN REG REFORM BILL approved 15-0 by the Senate Governmental Affairs Committee during a March 23 markup. The congressional review provision is taken largely from the "Comprehensive Regulatory Reform Act" (S 343) as reported out by the Senate Judiciary/Oversight & Courts Subcommittee March 14, although the legislation reported out of Government Affairs is based on Committee Chairman Roth's (R-Del.) own regulatory reform bill, S 291.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth